Selection criteria for the clinical use of the newer antiepileptic drugs

CNS Drugs

Volumn 17, Issue 6, 2003, Pages 405-421

  Deckers, Charles L P ^a,b   Knoester, P D ^a   De Haan, G J ^b   Keyser, A ^a   Renier, W O ^a   Hekster, Y A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Dutch Epilepsy Clinics Foundation   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CORTICOTROPIN; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; ANXIETY DISORDER; APLASTIC ANEMIA; ASTHENIA; ATAXIA; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIPLOPIA; DRUG CHOICE; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEADACHE; HUMAN; HYPONATREMIA; INFANTILE SPASM; INFECTION; INSOMNIA; LENNOX GASTAUT SYNDROME; LICENSING; LIVER FAILURE; LIVER TOXICITY; MAINTENANCE THERAPY; MENTAL DEFICIENCY; METHODOLOGY; MONOTHERAPY; MYOCLONUS SEIZURE; NEUROTOXICITY; OSCILLOPSIA; PARESTHESIA; PATIENT SELECTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PSYCHOSIS; RASH; REVIEW; RHINITIS; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; VERTIGO; VISUAL FIELD DEFECT; WEST SYNDROME;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS; DRUG EVALUATION; DRUGS, INVESTIGATIONAL; EPILEPSY; HUMANS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 0037540053     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317060-00003     Document Type: Review

References (112)

1. Cockerell OC, Johnson AL, Sander JWAS, et al. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet 1995; 346: 140-4
2. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991; 41: 1785-9
3. Morrell MJ, McLean MJ, Willmore LJ, et al. Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. Seizure 2000; 9: 241-8
4. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures: US Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993; 43: 2284-91
5. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized, clinical trial. Neurology 2000; 55: 236-42
6. Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled dose-ranging trial in refractory partial epilepsy. Epilepsia 2000; 41: 1597-607
7. Uhtman M, Rowan J, Ahmann PA, et al. Tiagabine for complex partial seizures. Arch Neurol 1998; 55: 56-62
8. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400- and 600mg daily dosages. Neurology 1996; 46: 1684-90
9. French JA, Mosier M, Walker S, et al. A double-blind, placebo-controlled study of vigabatrin 3 g/day in patients with uncontrolled partial seizures. Neurology 1996; 46: 54-61
10. Faught E, Ayala R, Montouris GG, et al. Controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774-9
11. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA 2002; 287: 2273-5
12. Pellock JM. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf 1999; 21: 225-39
13. Hardus P, Verduin WM, Engelsman M, et al. Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia 2001; 42: 262-7
14. Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38: 859-80
15. Cramer JA, Fisher R, Ben-Menachem E, et al. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999; 40: 590-600
16. Löscher W. New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 1998; 342: 1-13
17. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999; 40 Suppl. 5: 2-10
18. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996; 37 Suppl. 6: 4-11
19. Macdonald RL. Is there a mechanistic basis for rational polypharmacy? In: Homan RW, Leppik IE, Lothman EW, et al., editors. Rational polypharmacy. Amsterdam: Elsevier Science BV, 1996: 79-93
20. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Progr Neurobiol 1999; 58: 31-59
21. Löscher W, Hönackp D, Bloms-Funke P. The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res 1996; 735: 208-16
22. Kuzniecky R, Ho S, Pan J, et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 2002; 58: 368-72
23. Taylor CP. Gabapentin: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 321-34
24. Margineanu DG, Klitgaard H. Levetiracetam: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 419-27
25. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43: 9-18
26. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 135: 659-72
27. Deckers CLP, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41: 1364-74
28. Stephen LJ, Brodie MJ. Letter to the editor. N Engl J Med 2002; 346: 294
29. Wong ICK, Mawer GE, Sander JWAS, et al. A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. Epilepsia 2001; 42: 1354-8
30. Brodie MJ, Yuen AWC. Lamotrigine substitution study: evidence for synergism with valproate? 105 Study Group. Epilepsy Res 1997; 26: 423-32
31. Elferink AJA, van Zwieten-Boot BJ. Analysis based on number needed to treat shows differences between drugs studied [letter]. BMJ 1997; 314: 603
32. McDonnell GV, Morrow JI. An audit of the new antiepileptic drugs in clinical neurological practice. Seizure 1996; 5: 127-30
33. Wong ICK, Chadwick DW, Fenwick PBC, et al. The long-term use of gabapentin, lamotrigine and vigabatrin in patients with chronic epilepsy. Epilepsia 1999; 40: 1439-45
34. Datta PK, Crawford PM. Refractory epilepsy: treatment with new antiepileptic drugs. Seizure 2000; 9: 51-7
35. Lhatoo SD, Wong ICK, Polizzi G, et al. Long-term retention rates of lamotrigine, gabapentin and topiramate in chronic epilepsy. Epilepsia 2000; 41: 1592-6
36. Collins TL, Petroff OAC, Mattson RH. A comparison of four new antiepileptic medications. Seizure 2000; 9: 291-3
37. Krakow K, Walker M, Otoul C, et al. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001; 56: 1772-4
38. ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998; 39: 799-803
39. Czapinski PP. Evaluation of the effectiveness and safety of the first new-generation antiepileptic drug add-on therapy in managing patients with drug-resistant epilepsy. Epilepsia 2001; 42 Suppl. 7: 84-5
40. Chadwick DW, Anhut H, Greiner MJ. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures: International Gabapentin Monotherapy Study Group. Neurology 1998; 51: 1282-8
41. Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly-diagnosed epilepsy [abstract]. Epilepsia 2001; 42 Suppl. 7: 177
42. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy: UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476-9
43. Reunanen M, Dam M, Yuen AWC. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996; 23: 149-55
44. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy: the UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37: 81-7
45. Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a doubleblind comparison with phenytoin. Epilepsia 1999; 40: 601-7
46. Dam M, Ekberg K, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly-diagnosed previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6
47. Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195-204
48. Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451-60
49. Brodie MJ, Privitera MD, Neto W, et al. Topiramate, carbamazepine and valproate monotherapy: a unique, comparative trial in newly diagnosed epilepsy. Epilepsia 2000; 42 Suppl. Buenos Aires
50. Arroyo S, Sander JWAS. Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten. Neurology 1999; 53: 1170-4
51. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255-60
52. Chadwick D, Leiderman DB, Sauermann W, et al. Gabapentin in generalized seizures. Epilepsy Res 1996; 25: 191-7
53. Trudeau V, Myers S, LaMoreaux L, et al. Gabapentin in naive childhood absence epilepsy: results form two double-blind, placebo-controlled, multicenter studies. J Child Neurol 1996; 11: 470-5
54. Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Paediatr Drugs 2001; 3: 397-403
55. Mikati MA, Holmes GL. Lamotrigine in absence and primary generalized epilepsies. J Child Neurol 1997; 12 Suppl. 1: 29-37
56. Beran RG, Berkovic SF, Dunagan FM, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 1998; 39: 1329-33
57. Stephen LJ, Brodie MJ. Lamotrigine: clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, et al. editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 389-402
58. Kustra RP, Morris G, Schimschock JR, et al. Lamotrigine monotherapy in patients with juvenile myoclonus epilepsy: focus on seizure and myoclonus freedom. Epilepsia 2001; 41 Suppl. 7: 181-2
59. Dean JC, Muraoka LM, Wiser TH, et al. Outcomes of switch therapy in seizure patients: divalproex sodium to lamotrigine [abstract]. Epilepsia 2001; 42 Suppl. 7: 178
60. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine [abstract]. Neurology 2000; 55: 1758
61. Kasteleijn-Nolst Trenite DGA, Marescaux C, Stodieck S, et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs: evaluation of the piracetam analogue. Epilepsy Res 1996; 25: 225-30
62. Genton P, Gelisse P. Antimyoclonic effects of levetiracetam. Epileptic Disord 2000; 2: 209-12
63. Krauss GL, Abou-Khalil B, Sheth SG, et al. Efficacy of levetiracetam for treatment of drug-resistant generalized epilepsy [abstract]. Epilepsia 2001; 41 Suppl. 7: 181
64. Murphy K, Delanty N. Primary generalized epilepsies. Curr Treat Options Neurol 2000; 2: 527-42
65. Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002
66. Montouris GD, Biton V, Rosenfeld WE, et al. Nonfocal generalized tonic-clonic seizures: response during long-term topiramate treatment. Epilepsia 2000; 41 Suppl. 1: 77-81
67. Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998; 39: 1324-8
68. Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 2000; 52: 1882-7
69. Dooley JM, Camfield PR, Smith E, et al. Topiramate in intractable childhood onset epilepsy: a cautionary note. Can J Neurol Sci 1999; 26: 271-3
70. Cross H. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 2002; 11: 406-10
71. Vigabatrin Paediatric Advisory Group. Guideline for prescribing vigabatrin has been revised. BMJ 2000; 320: 1404-5
72. Mikati MA, Lepejian GA, Holmes GL. Medical treatment of patients with infantile spasms. Clin Neuropharmacol 2002; 25: 61-70
73. Lux AL, Edwards SW, Osborne JP, et al. Revised guideline for prescribing vigabatrin in children: guideline's claim about infantile spasms is not based on appropriate evidence. BMJ 2001; 322: 236-7
74. Ben-Menachem E. Vigabatrin. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 855-63
75. Peters DH, Sorkin EM. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760-87
76. Leppik IE. Zonisamide. Epilepsia 1999; 40 Suppl. 5: 23-9
77. Pellock JM, Perhach JL, Sofia RD. Felbamate. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 301-18
78. Ramsay ER, Pryor FM. Gabapentin: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 355-9
79. Gilliam F, Vasquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998; 51: 1018-25
80. Besag FMC, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39: 183-7
81. French JA, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001; 47: 77-90
82. Sisodiya SM, Sander J, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res 2002; 48: 217-9
83. Schmidt D, Gram L, Brodie M, et al. Tiagabine in the treatment of epilepsy: a clinical review with a guide for the prescribing physician. Epilepsy Res 2000; 41: 245-51
84. Shorvon S. Handbook of epilepsy treatment. Oxford: Blackwell Science, 2000
85. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999; 52: 321-7
86. Lee BI. Zonisamide: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 892-8
87. Besag FMC. Behavioral effects of the new anticonvulsants. Drug Saf 2001; 24: 513-36
88. Mula M, Trimble MR, Liu R, et al. Levetiracetam and neuropsychiatric adverse events in patients with epilepsy. Epilepsia 2002; 43 Suppl. 8: 56-7
89. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53 Suppl. 2: 53-67
90. Biton V. Levetiracetam: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 442-7
91. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001; 24: 969-78
92. Reife R, Pledger G, Wu S-C. Topiramate as add-on therapy: pooled analysis of randomized controlled clinical trials in adults. Epilepsia 2000; 41 Suppl. 1: 66-71
93. Greenwood RS. Adverse effects of antiepileptic drugs: a systematic review. Epilepsia 2001; 41 Suppl. 2: 42-51
94. Kaufman KR, Lepore FE, Keyser BJ. Visual field defects and tiagabine: a quandary. Seizure 2001; 10: 525-9
95. Schachter S. Tiagabine: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 711-5
96. Sills GJ, Patsalos PN, Butler E, et al. Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001; 57: 196-200
97. Banta JT, Hoffman K, Dudenz DL, et al. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 2001; 132: 112-4
98. Elger CE, Fernandez G. Options after the first antiepileptic drug has failed. Epilepsia 1999; 40 Suppl. 6: 9-12
99. Natsch S, Hekster YA, Keyser A, et al. Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf 1997; 17: 228-40
100. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia 2000; 41 Suppl. 8: 6-15
101. Johannessen SI, Tomson T. Laboratory monitoring of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 103-11
102. Arroyo S, Kramer G. Treating epilepsy in the elderly: safety considerations. Drug Saf 2001; 24: 991-1015
103. Genton P, Bauer J, Duncan S, et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001; 42: 295-304
104. Isojärvi JIT, Tauboll E, Tapanainen JS, et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 2001; 42: 305-10
105. Herzog AG, Schacter SC. Valproate and the polycystic ovaria syndrome: final thoughts. Epilepsia 2001; 42: 311-5
106. Pisani F, Richens A. Lamotrigine: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 408-16
107. Glauser TA. Expanding first-line therapy options for children with partial seizures. Neurology 2000; 55 Suppl. 3: 30-7
108. Sachdeo RC, Karia RM. Topiramate: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 760-4
109. Crawford P, Brown S, Kerr M, et al. Efficacy of gabapentin in adults with learning disability and resistant epilepsy: a randomised open-label comparative study. Epilepsia 2000; 41 Suppl. Florence: 96-7
110. Veendrick-Meekes MJBM, Beun AM, Carpay JA, et al. Use of lamotrigine in patients with mental retardation and epilepsy: an interim analysis of a double blind study with evaluation of behavioural effects. Epilepsia 2000; 41 Suppl. Florence: 96-7
111. Singh BK, White-Scott S. Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure 2002; 11: 47-50
112. Gaily E, Granstrom ML, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intellect Disabil Res 1998; 42 Suppl. 1: 41-5